1. Home
  2. PCRX vs FAX Comparison

PCRX vs FAX Comparison

Compare PCRX & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • FAX
  • Stock Information
  • Founded
  • PCRX 2006
  • FAX 1986
  • Country
  • PCRX United States
  • FAX United States
  • Employees
  • PCRX N/A
  • FAX N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • FAX Investment Managers
  • Sector
  • PCRX Health Care
  • FAX Finance
  • Exchange
  • PCRX Nasdaq
  • FAX Nasdaq
  • Market Cap
  • PCRX 1.2B
  • FAX 654.7M
  • IPO Year
  • PCRX 2011
  • FAX N/A
  • Fundamental
  • Price
  • PCRX $23.22
  • FAX $16.29
  • Analyst Decision
  • PCRX Buy
  • FAX
  • Analyst Count
  • PCRX 8
  • FAX 0
  • Target Price
  • PCRX $28.38
  • FAX N/A
  • AVG Volume (30 Days)
  • PCRX 569.8K
  • FAX 833.6K
  • Earning Date
  • PCRX 07-29-2025
  • FAX 01-01-0001
  • Dividend Yield
  • PCRX N/A
  • FAX 12.09%
  • EPS Growth
  • PCRX N/A
  • FAX N/A
  • EPS
  • PCRX N/A
  • FAX N/A
  • Revenue
  • PCRX $702,772,000.00
  • FAX N/A
  • Revenue This Year
  • PCRX $7.54
  • FAX N/A
  • Revenue Next Year
  • PCRX $10.78
  • FAX N/A
  • P/E Ratio
  • PCRX N/A
  • FAX N/A
  • Revenue Growth
  • PCRX 3.08
  • FAX N/A
  • 52 Week Low
  • PCRX $11.16
  • FAX $2.33
  • 52 Week High
  • PCRX $27.64
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.42
  • FAX 70.57
  • Support Level
  • PCRX $22.82
  • FAX $15.91
  • Resistance Level
  • PCRX $24.36
  • FAX $16.40
  • Average True Range (ATR)
  • PCRX 0.69
  • FAX 0.21
  • MACD
  • PCRX -0.12
  • FAX 0.05
  • Stochastic Oscillator
  • PCRX 17.09
  • FAX 89.13

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

Share on Social Networks: